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After  in  vitro mixed  lymphocyte culture,  cytotoxic lymphocytes develop which 
have specificity for components of the main histocompatibility complex (MHC) 1 of 
the stimulating  lymphocyte population  (1,  2).  The effector cells were  found to be 
directed mainly against class I histocompatibility antigens, that is, the H2-K and H2- 
D  antigens  in  the  mouse  (3),  and  the  HLA-A  or  HLA-B  antigens  in  man  (4). 
Cytotoxicity against  HLA-C was  quite weak  (5).  The role of class II antigens  was 
thought  to  be  that  of providing  a  necessary amplifying effect  (6,  7),  however,  it 
became clear later that incompatibility at HLA-D was not necessary for cell-mediated 
lysis (CML) to occur (8). In mice, class I antigens (H2-K and H2-D) alone, or class II 
antigens (H2-I) alone, were able to generate strong CML (9). 
Most  investigators  who  have  performed studies  with  human  lymphocytes have 
concluded that  HLA-D region products do not serve as targets for CML (6,  7,  10). 
However, cytotoxicity directed at MHC products other than the known class I (HLA- 
A, B, or C) specificities has frequently been observed (8, 11-13). In spite of the failure 
to detect cytotoxicity against  HLA-D products,  the  question of their role was  not 
considered resolved by several authors (14-16). In view of the analogy between HLA- 
D and the I region in the mouse, reports that products of H2-I serve as strong targets 
for CML (17-19) were particularly relevant to this question. 
In the present experiments the possibility that products of the HLA-D region may 
act  as target antigens  in CML was  investigated by using monocytes as target cells. 
The  effector cells  were  generated  in  vitro  by  culture  with  stimulating  cells  from 
unrelated donors, matched in the HLA-A and B regions, but mismatched for HLA- 
D.  The  results  obtained  with  a  variety  of target  cells,  showed  that  cytotoxicity 
correlated with HLA-D, as determined by serologic typing. Specific blocking experi- 
ments  with  unlabeled  monocytes  have  confirmed  that  products  of HLA-D  were 
recognized by the cytotoxic lymphocytes. 
Materials and Methods 
Study Subjects.  Blood  donors  used  in  these studies were  members  of our  permanent  tissue 
typing panel. They have been typed for HLA-A, B, C, D, and DR, repeatedly over a period of 
years. 
* Supported in part by grant  1-P01-AM-19329-03 from the National Institutes of Health, U. S. Public 
Health Service. 
1 Abbreviations used in  this paper:  CML, cell-mediated lysis; HTC, homozygous typing cells; CML, 
cell-mediated lysis. 
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HLA  Typing.  The typing reagents used included local sera, sera obtained by exchange with 
other investigators, and those exchanged in the  7th International Workshop. Testing for the 
HLA-A, B, C antigens was performed by using a standard microcytotoxicity method (20). The 
HLA-DR typing was performed on both purified B cells and monocytes as described in detail 
elsewhere  (21, 22).  The  HLA-D  typing was  obtained by  mixed  lymphocyte culture with 
homozygous typing cells (HTC) as previously described (23). 
Cell Preparation.  Venous blood was drawn into heparinized containers and diluted with an 
equal volume of RPMI-1640 medium before centrifugation on Ficoll-Hypaque (Lymphoprep, 
Nyegaard, Oslo)  as described by BSyum (24). The resultant peripheral blood mononuclear 
cells, were washed twice with RPMI-1640, before suspension in serum-enriched RPMI-1640 
medium. Pooled normal human serum obtained from 40  healthy male donors, was  used at 
either 20% concentration (RPMI-20% serum) or 10% (RPMI-10% serum). 
Monocytes.  Peripheral blood mononuclear cells in RPMI-20% serum were placed in 100  × 
20-mm plastic dishes  (Kimble, Div. of Owens-Illinois, Toledo, Ohio) and incubated overnight 
at 37°C, in a humid atmosphere containing 5% CO2 and 95% air. By repeatedly washing the 
dish with RPMI-1640 medium, the nonadherent cells were removed. The adherent cells were 
then resuspended in RPMI-20% serum with the aid of a  rubber policeman. Such cells were 
greater  than  95%  viable  by  trypan  blue  exclusion  and  70-80%  ingested  latex  particles. 
Euchrysine staining (22) showed 70-80% of the cells to have the red cytoplasmic fluorescence 
and bean shaped nuclei characteristic of monocytes. 
B-Cell Lymphoblastoid Cell Lines.  Peripheral blood mononuclear cells from selected  HLA-D 
homozygous donors, were transformed by using the B95-8 strain of the Epstein-Barr virus (25) 
with the kind help of Dr.  Graham Smith, Department of Internal Medicine, University of 
Texas Health Science Center at Dallas. After 3-5 wk, the cell lines with characteristics of B 
lymphocytes were established in culture. Cells were stored frozen in liquid nitrogen and thawed 
for use as needed for these experiments. 
Generation ofCytotoxic Effector Cells.  Peripheral blood mononuclear  cells from selected donors, 
were cultured with stimulating cells, which had been X-irradiated (3,000 rads from a  137Cs 
source) in 12 ×  75 mm round-bottomed tubes (BioQuest, BBL & Falcon Products, Cockeysville, 
Md.). 3 million responder cells and 1.5  X  108 stimulator cells were cultured in 3.0 ml RPMI- 
10% serum at 37°C, in a  humid atmosphere of 5% CO2, 95% air. Responder cells were  also 
cultured in the presence of autologous X-irradiated cells for use as controls. After 6 d of culture 
the cells were resuspended and adjusted to a concentration of 10  ×  106 per ml for use in the 
cytotoxicity assay. 
Cytotoxicity Assay.  Monocytes to be used as target cells were labeled with radioactive sodium 
51  S  chromate (Na2 CrO4, Amersham Corp., Arlington Heights, Ill.). To 5-10 ×  10  monocytes in 
51  o  0.2 ml RPMI-20% serum was added 200/~Ci of  Cr. The cells were then incubated at 37  C, for 
1 h with occasional shaking, washed three times with RPMI-20% serum at 4°C, and suspended 
at a concentration of 105 cells per ml in RPMI-10% serum. 
The cytotoxicity assays were performed in round bottom microtiter plates (Linbro Chemical 
Co., New Haven, Conn.). Each reaction well contained 5 X  103 target cells and 5 ×  105 effector 
cells, or autologous controls, in a  total vol of 0.2  ml. After incubation at  37°C, for 6 h, the 
radioactive supernates were collected into absorbing elements of cellulose  acetate  (Titertek, 
Flow Laboratories, Inc., Rockville, Md.) and counted in a gamma counter (Packard Instrument 
Co., Inc., Downers Grove, Ill.). 
Inhibition by Unlabeled Cells.  In some experiments, cells that were not labeled with radioactive 
chromium were added to the cytotoxicity assay,  to determine their effect on target cell lysis. 
The unlabeled cells were added to the microtiter wells  at the beginning of the cytotoxicity 
assay. Their number varied in different experiments from 5  X  104 to 4  ×  105 per well. 
Calculation of Results.  The results of CML experiments were expressed as percent cytotoxicity, 
according to the formula: 
percent cytotoxicity =  ABx.T* -  AAx.T*/Max.T* -  AAx.T*  ×  100, 
where ABx.T* represents 5XCr released from target cell T* by the effector  cells stimulated by 
allogeneic cells, AAx.T* represents the spontaneous release due to cells from the same responder 
cultured with autologous stimulators and Max.T* is the maximal release of radioisotope from 
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release  in  these  experiments was  89  :t:  1.3% of the total  found radioactivity. Spontaneous 
release in these experiments equalled 23 +  0.9%. 
In some experiments in which  the inhibition of CML was  investigated,  results were also 
expressed as percent inhibition.  This was calculated as follows: 
percent inhibition --  (1 -  [percent cytotoxicity with unlabeled cells/ 
percent cytotoxicity without unlabeled cells]) ×  100. 
When cytotoxicity was not inhibited or it was increased after addition of the unlabeled cells, 
the percent inhibition was expressed as zero. 
Statistical evaluation of the data was performed by chi-square analysis with Yates' correction 
and by the Student's t test. 
Results 
Generation of Effector  Cells by  Culture with  Stimulating  Lymphocytes Mismatched for the 
HLA-D Region.  To determine whether effector cells can  be generated in  vitro by 
culture with cells compatible except for HLA-D, responding cells R.M. were stimu- 
lated in vitro by cells from an unrelated donor G.S. The HLA phenotype of R.M. was 
HLA-A1,  A2,  B8,  B18,  DW2,  DW8,  DRW2,  WIa8,  and  G.S.  was  known  to  be 
homozygous HLA-A1, B8, DW3, DRW3 on the basis of family and mixed lymphocyte 
culture studies. No HLA-C alleles were detectable in the stimulator or the responder. 
To determine whether cytotoxic lymphocytes developed against determinants of the 
HLA-D  region,  a  panel  of DRW3-positive  and  DRW3-negative  individuals  was 
selected for testing. The details of HLA-A, B, C, and DR antigens detected in these 
persons  by serologic typing is  shown  in  Table I.  The results of cell-mediated lysis 
experiments  with  chromium-51-1abeled  target  monocytes  are  shown  in  Table  II. 
Cytotoxicity correlated with the presence of DRW3. When DRW3 was absent from 
the target cells, cytotoxicity was between 5 and  13%. In contrast, the same effector 
cells produced much higher chromium release (53-76%)  from the monocytes of the 
DRW3-positive donors. 
Cell-Mediated Lysis with Other Effector Cells Directed against the HLA-D Region.  In Fig. 
1, the first effector cell was developed by culturing cells from responder R.M. and the 
DW3,  DRW3  homozygous stimulator, J.G.  The results  show that  cytotoxicity was 
present when the target cells were DRW3 positive like the stimulator. 
The effector cells in the second experiment shown in Fig. 1, were generated between 
responder R.G.  (HLA-A1, A2, B8, B12, DRW1, DRW3) with stimulating cells J.W. 
(HLA-A1, A2, B8, B12, DRW4).  The stimulating antigen  in  this combination was 
DRW4  for which J.W.  was  homozygous. The  test  panel  consisted  of four donors 
having DRW4,  who gave cytotoxicity between  27  and  50% and  three donors who 
were DRW4 negative, whose cells gave very low levels of chromium release (4-1 I%). 
In  this  series  of experiments  20  target  cells  were  DRW3  positive  and  the  mean 
cytotoxicity was 46.5  ±  2.9%.  The mean cytotoxicity of 14 target cells negative for 
DRW3  was only 6.4  ±  1.1%. The difference between the means of the two groups 
was highly significant (P <  10-4). Similarly, with effeetor cells primed against DRW4 
there was a  highly significant difference (P <  0.001)  in cytotoxicity between target 
cells  having  the  HLA-D  determinant  matched  to  the  stimulator  (30.0  ±  4.7%) 
compared to those who did not (3.8  ±  1.8%). 
Role of HLA-D and D.R. in Cell-Mediated Lysis.  It is possible to identify specificities 
coded by the HLA-D region by serologic and by mixed lymphocyte culture typing. 
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TABLE  I 
HLA Phenotypes of Donors of Target Cells used in Table II 
Target cells 
HLA Antigens 
A  B  C  DR 
P.D.  W24, --  W35, W37  4, 6  W._3, W4 
L.K.  1, 2  7, 8  6, --  W._33, -- 
P.P.  1, W24  8, --  ,  W3, -- 
B.B.  1, --  9, --  ,  Wl, W_..~3 
C.K.  1, 3  7, 8  ,  WI, W_..~3 
L.Mc.  W32, --  14, W40  ,  WT, -- 
P.S.  3, 11  14, W38  ,  W1, -- 
H.S.  1, --  12, 17  5, 6  W6, W8 
S.G.  1, 2  5, 12  ,  W2, W4 
R.M.  1, 2  8,18  ,  W2, W8 
TABLE  II 
Cell-Mediated Lysis of Target Monocytes by Effector Cells Exposed to HLA-DR W3 and Associated 
Determinants of the HLA-D Region* 
Radioactivity released§ 
Target cells  DR W3:~  Cytotoxicityll 
Maximal  Spontaneous  Experimental 
cpm  % 
P.D.  +  2,655  491  1,639  53 
L.K.  +  2,232  381  1,510  60 
P.P.  +  1,907  478  1,575  76 
B.B.  +  3,236  554  2,281  64 
C.K.  +  2,340  386  1,671  65 
L.Mc.  -  2,171  393  524  07 
P.S.  -  2,474  428  597  08 
H.S,  -  2,703  545  821  13 
S,G.  -  2,473  445  549  05 
R.M.  -  2,228  378  515  07 
* Effector cells were generated by culturing responder R.M.(HLA-AI, A2, B8, B18,  DRW2, WlaS) with 
stimulating cells G.S.(HLA-AI, A1, B8, B8, DRW3, DRW3). 
:~ Complete HLA typing given in Table I. 
§ Target cells were labeled with Na2 SlCrO4; maximal release was obtained with detergent; spontaneous 
release determined in mixtures of labeled target ceils with RM. RMx control effectors,  spontaneous and 
experimental assay mixtures were incubated for 6 h. 
II Percent cytotoxicity calculated by using the formula given in text. 
related  (DR)  antigens. The  lymphocyte  stimulating  determinants  identified by MLC 
typing  with  HTCs  are  more  restricted.  Thus  some  of our  panel  donors  presented  a 
given  broad  HLA-DR  specificity  without  the  HLA-D  antigen  (by  MLC)  which  is 
usually  associated  with  it  in  Caucasians.  When  cells  from  such  D/DR  discrepant 
donors were  used as targets with effector cells stimulated  against  the HLA-D  region, 
the  results  showed,  that  presence  of the  HLA-DR  determinant  was  sufficient  for 
cytotoxicity to occur. This was true also with target cell P.C.,  known  by family study 
to have HLA-DW  11, DRW4  on the paternal  haplotype.  Yet P.C.  ceils were killed by 
effector lymphocytes  primed  against  a  DW4,  DRW4  stimulator.  The  magnitude  of CONLETH  FEIGHERY AND PETER  STASTNY  489 
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Fla.  1.  Celt-mediated lysis directed against  HLA-D region determinants. Effector cells were 
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FIG. 2.  Cell-mediated cytotoxicity against HLA-D region determinants. Effeetor cells RM.JG, 
and RM.GS, stimulated against DRW3, RG.JW, against DRW4. The target monocytes used in 
these experiments were from donors matched for the stimulating HLA-D and DR antigens 0, 
matched for the stimulating HLA-DR but not HLA-D (as determined by MLC typing) A; or not 
matched for either HLA-D or DR C) 
cytotoxicity obtained when HLA-DR-positive, HLA-D-negative cells were used was 
similar to that obtained with target cells having both determinants matched with the 
stimulating cells  (Fig.  2),  The specificity of the cytotoxic effector lymphocytes thus 
appeared to correlate with target specificities recognized by serum antibodies, rather 
than with specificities determined in MLC by proliferating T  cells. 
Antigen Specificity of Inhibition by Unlabeled Monocytes and Cultured B  Cells.  Results of 
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TABLE III 
Specificity of Blocking of Cell-Mediated Lysis against HLA-D Region-Associated Determinants by 
Unlabeled Monocytes 
Priming of effector  Exp.  cells*  Target cell DR  Blocking  cell DR  Cytotoxicity  Inhibition 
1  DRW3  W3 
2  DRW3  W3 
3  DRW2  W2 
4  DRW2  W2 
5  DRW4  W4 
%  % 
--  33  -- 
W2, W3  13  61 
W3, --  12  64 
W2, W4  41  0 
W1, W2  37  0 
--  69  -- 
W3, --  12  83 
W3, W3  7  90 
W2, W4  64  7 
--  11 
W2, --  0  100 
W4, --  10  9 
--  13  -- 
W2, W4  0  100 
W1, W3  14  0 
--  11  -- 
W2, W4  1  91 
W1, --  10  9 
* Effectors in exp. 1 and 2 were produced as in Fig. 1; effector cells in exp. 3 and 4 were produced by 
priming a responder W.S. (HLA-A3, AI 1, B12, B15, C1, -DRW4, DRW7) with cells from stimulator 
U.B.(HLA-A3, A11, B7, -DRW2, DRW2), target cells and blocking cells in these experiments did not 
have HLA-B7; effector cells in exp. 5, were produced as in Table II. 
specificity of the blocking effect are shown in Table III. In each case monocytes from 
unrelated  donors,  known  to  be  positive  for  the  HLA-DR  antigens  to  which  the 
cytotoxic  cells  were  primed,  were  found  to  inhibit cytotoxicity.  Monocytes  from 
donors who did not have a HLA-DR antigen matched with the target cell were found 
not to block. The specificity of monocyte blocking was examined in experiments with 
unlabeled monocytes from  41  donors, by using effector cells primed against HLA- 
DRW2,  DRW3,  DRW4.  Blocking was  achieved  23  times  when  the  antigen was 
present and no inhibition  was observed in 14 tests, when the antigen was absent. One 
cell preparation having the correct antigen failed to inhibit. In three instances there 
was a  false positive result. Two of the three cells which blocked despite absence of the 
sensitizing antigen  (DRW4),  belonged to  an  individual positive  for  DRW7.  This 
antigen is  known to  cross-react  with  DRW4,  the  target  antigen in  this  particular 
experiment. The chi square obtained from these results is 23 (P <  l0  s) indicating that 
there was a  strong correlation between the presence of a  specific HLA-DR antigen 
and the capacity to inhibit CML. 
Similar results were obtained when cultured lymphoblastoid cells were used instead 
of isolated monocytes. These cell lines are known to have the characteristics of B cells, 
including the  presence  of  HLA-D  and  HLA-DR  specificities.  Only the  cell  lines 
having the correct  HLA-DR specificity were  found to be capable of inhibiting the 
chromium  release.  The  correlation  between  CML  inhibition and  the  HLA-DR 
antigens in monocytes and B  cells from unrelated donors strongly suggests that  the 
HLA-D region product itself was responsible for the inhibitory effect. CONLETH FEIGHERY AND PETER STASTNY  491 
Discussion 
Previous investigators have either failed to find cytotoxicity associated with HLA- 
D,  or were  unable  to  draw  firm  conclusions  regarding  this  point  (14-16).  In  the 
present  experiments,  effector cells  were  generated  among  HLA-A  and  B  region 
compatible, HLA-D region incompatible, unrelated individuals. Because of identity 
in  the  HLA-A and  B  regions,  effector cells obtained  from such  cultures could  be 
directed  against  determinants  encoded  by  the  HLA-D  region,  or  against  other 
determinants which are not  identified by current typing methods.  The stimulating 
cells were HLA-D homozygous so the effectors were primed only against one HLA-D 
specificity. In some of the cells used, no HLA-C alleles were detectable with antisera 
identifying HLA-CW1  through CW6, but it seems unlikely that  HLA-C associated 
determinants  would  have  played an  important  role.  Because  HLA-C and  HLA-B 
alleles are  in  strong linkage disequilibrium,  there is  a  good chance,  if the  HLA-B 
alleles were matched, that the C  alleles would have been matched also. In addition, 
products of HLA-C are known to be poorly antigenic (26) and known not to be strong 
targets for CML (5). 
The evidence from the present experiments that HLA-D associated products serve 
as targets for cell mediated cytotoxicity are in contrast with multiple previous reports 
to the contrary by other investigators (6,  7,  10).  It should be remembered however, 
that beginning with the report by Lightbody et al. (2) most human CML experiments 
have been carried out by using human T  cells undergoing blastic transformation after 
culture  with  phytohemagglutinin.  Although  there  is  general  agreement  that  the 
majority of T  lymphocytes obtained from human peripheral blood do not express the 
HLA-DR determinants there is controversy as to whether or not these antigens appear 
in human T  cells during blastic transformation after in vitro culture with mitogens. 
Colombani et al.  (27)  have reported that human T-cell blasts obtained after culture 
with phytohemagglutinin or concanavalin A, express HLA-DR specificities detectable 
by complement fixation. Only a  small population of concanavalin A-induced blasts 
in the mouse was reported to be killed by anti-Ia serum and complement (28). In the 
present  experiments  the  target  cells  were  peripheral  blood  monocytes isolated  by 
adherence to plastic dishes. It is well established that human monocytes, obtained in 
this manner, express HLA-DR antigens  (29,  30) and it is known that monocytes are 
sensitive targets for chromium release cytotoxicity assays (31). 
Our  results  showed  that  using a  panel  of unrelated  target  cells the  cytotoxicity 
reactions correlated with  the  HLA-DR  antigens  of the  target  cell donors.  Effector 
cells used were primed with cells mismatched for HLA-DRW2, DRW3, or DRW4. 
To be killed,  the donors of the target cells had  to possess  the HLA-DR antigen to 
which the effector cell had been exposed in the sensitizing culture. These results were 
interpreted to mean that cytotoxicity was directed against HLA-D region products or 
very closely linked determinants. 
The cytotoxicity inhibition experiments with  unlabeled target cells, lend further 
support to the notion that  HLA-D region associated determinants were involved in 
these  cytotoxicity reactions.  Blocking with  monocytes from  unrelated  donors  was 
found to depend on the presence of the correct HLA-D alleles. The correlation of 
HLA-DR typing of the monocytes capable of blocking, with that of the target cells, 
was observed for DRW2, DRW3, and DRW4. One interesting exception was a  false 
positive result obtained in  an experiment in which cells from a  donor positive for 
HLA-DRW7 were found to block cytotoxicity presumed to be directed against HLA- 492  HLA-D  REGION-ASSOCIATED  DETERMINANTS 
DRW4. DRW4 and DRW7 antigens are known to be cross-reactive when examined 
by using antibodies  against  B  lymphocytes (32).  The  observation of similar  cross- 
reactivity in cold-cell blocking experiments suggests that some of the cytotoxic effector 
cells were recognizing determinants shared by DRW7 and DRW4. 
At  the  present  time HLA-D region alleles are  recognized by mixed  lymphocyte 
culture  typing  (33),  by  primed  lymphocyte culture  typing  (34),  and  by serologic 
typing with isolated B  cells or monocytes (22,  32).  It is not known whether one or 
several gene products are involved. From the results it is not possible to decide whether 
the HLA-D region determinants recognized by cytotoxic lymphocytes are the same as 
those recognized by the other techniques. The HLA-DR specificities are known to be 
broader than the HLA-D determinants defined by typing with homozygous typing 
cells  (35).  Thus a  number of donors used  as CML targets were HLA-DR  positive 
HLA-D negative. Monocytes from such donors were found to be good targets as long 
as the correct HLA-DR specificity was present. 
The results of the present studies, together with the finding that antibodies against 
HLA-DR effectively inhibited the cytotoxicity reactions,  2 suggest but do not prove, 
that  the same HLA-DR products were recognized by antibodies in the typing sera 
and by the cytotoxic lymphocytes. Cell mediated lympholysis has been considered to 
be an in vitro model of allograft rejection (9). The inhibition of cytotoxicity by anti- 
DR  antibodies  as  observed  in  the  present  experiments,  may be  a  model  of what 
happens in vivo during antibody enhancement of experimental grafts (36).  Perhaps 
the HLA-DR specificities serve as targets for cytotoxic lymphocytes in vivo as well as 
in vitro. 
Summary 
Effector cells for cell-mediated lysis (CML) were generated by in vitro culture of 
lymphocytes from selected donors with X-irradiated cells from unrelated subjects who 
were  HLA-D homozygous and  matched  to  the  responders  for the  antigens  of the 
HLA-A and HLA-B regions. By using chromium labeled monocytes as target cells, 
cytotoxicity was found to correlate with presence of HLA-D region antigens matching 
those of the stimulating cells.  Such CML reactions apparently directed at products of 
HLA-D, were inhibited by addition of unlabeled monocytes or B lymphocytes. These 
unlabeled  cells  had  to  be  matched  for HLA-D with  the  stimulating  cells used  to 
generate  the  effector populations.  The  results  suggested  that  products  of HLA-D, 
perhaps the DR antigens, were recognized by cytotoxic lymphocytes. 
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